Company
Trellis Bioscience
Clinical-stage biotech developing native human mAbs for intractable infectious diseases.
Also known as Trellis Bioscience, Inc.
- Status
- Operatingas of 2026-09-23
- Business model
- B2B
- Headquarters
- Redwood City, CA, United States
- Legal name
- Trellis Bioscience, Inc.
Claim, correct or request removal
Record updated 23 October 2026
About
Trellis Bioscience is a clinical-stage biotechnology company developing native human monoclonal antibodies (mAbs) to treat intractable infectious diseases.
Funding snapshot
- Total raised
- $18MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Undisclosed, $4.1M2024-10-04
Funding rounds
- Round, 2026
- $9.1M2026-01-30, SEC form D sold, 16 investors
- Round, 2024
- $4.1M2024-10-04, SEC form D sold
- Round, 2023
- $1.4M2023-04-20, SEC form D sold
- Round, 2022
- $985K2022-06-01, SEC form D sold
- Round, 2011
- $235K2011-10-27, SEC form D sold, 8 investors
- Round, 2010
- $22.9M2010-04-29, SEC form D sold
- Round, 2009
- $11.7M2009-07-08, SEC form D sold, 12 investors
Loading relationship preview